Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT

[1]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[2]  A. Malliani,et al.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use , 1996 .

[3]  G. Breithardt,et al.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. , 1996 .

[4]  M. Malik.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. , 1996, European heart journal.

[5]  R. Peters,et al.  Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. , 1995, British heart journal.

[6]  A. Camm,et al.  Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). , 1995, The American journal of cardiology.

[7]  S. Hohnloser,et al.  Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.

[8]  Lippincott Williams Wilkins,et al.  The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1994, European heart journal.

[9]  A. Camm,et al.  Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT). , 1994, European heart journal.

[10]  R. Peters,et al.  High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. , 1994, Journal of the American College of Cardiology.

[11]  Ralph Lazzara,et al.  The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1994, Circulation.

[12]  A. Camm,et al.  The European Myocardial Infarct Amiodarone Trial (EMIAT) , 1993 .

[13]  K. Teo,et al.  Critical review of the approaches to the prevention of sudden death. , 1993, The American journal of cardiology.

[14]  C. Furberg,et al.  Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.

[15]  F. Amann,et al.  Additional antianginal efficacy of amiodarone in patients with limiting angina pectoris. , 1993, American heart journal.

[16]  S. Yusuf,et al.  Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. , 1992, Journal of the American College of Cardiology.

[17]  A. Camm,et al.  A prospective study of the efficacy and safety of adjuvant metoprolol and xamoterol in combination with amiodarone for resistant ventricular tachycardia associated with impaired left ventricular function. , 1992, American heart journal.

[18]  P. Schwartz,et al.  Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. , 1992, Circulation.

[19]  Robert Lemery,et al.  Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.

[20]  A. Camm,et al.  Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. , 1991, Journal of the American College of Cardiology.

[21]  S. Connolly,et al.  Post‐Myocardial Infarction Mortality in Patients With Ventricular Premature Depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study , 1991, Circulation.

[22]  P. Podrid,et al.  Side effects of Amiodarone , 1982 .

[23]  Michael R. Rosen,et al.  The 'Sicilian Gambit' - A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms , 1991 .

[24]  M. Pfisterer,et al.  Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) , 1990, Journal of the American College of Cardiology.

[25]  J J Heger,et al.  Clinical features of amiodarone-induced pulmonary toxicity. , 1990, Circulation.

[26]  A. Camm,et al.  CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1990, Circulation.

[27]  A. Camm,et al.  CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1990, European heart journal.

[28]  M. Janse,et al.  Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. , 1989, Physiological reviews.

[29]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[30]  R. Harper,et al.  Amiodarone-induced hyperthyroidism: assessment of the predictive value of biochemical testing and response to combined therapy using propylthiouracil and potassium perchlorate. , 1988, Australian and New Zealand journal of medicine.

[31]  E. Mellits,et al.  Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. , 1987, Circulation.

[32]  A. Pinchera,et al.  AMIODARONE IODINE‐INDUCED HYPOTHYROIDISM: RISK FACTORS AND FOLLOW‐UP IN 28 CASES , 1987, Clinical endocrinology.

[33]  K. Ellenbogen,et al.  Cardiac function in patients on chronic amiodarone therapy. , 1985, American heart journal.

[34]  J P Miller,et al.  The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. , 1984, Circulation.

[35]  Seymour Furman,et al.  The North American Society of Pacing and Electrophysiology , 1984, Pacing and clinical electrophysiology : PACE.

[36]  C. Furberg.  Effect of antiarrhythmic drugs on mortality after myocardial infarction. , 1983, The American journal of cardiology.

[37]  L. Harris,et al.  Side Effects of Long-term Amiodarone Therapy , 1983, Circulation.

[38]  B. Pitt.  SUDDEN CARDIAC DEATH: ROLE OF LEFT VENTRICULAR DYSFUNCTION , 1982, Annals of the New York Academy of Sciences.

[39]  H T Davis,et al.  Ventricular Ectopic Beats and Their Relation to Sudden and Nonsudden Cardiac Death After Myocardial Infarction , 1979, Circulation.

[40]  J. Goldberg,et al.  Ventricular premature beats and mortality after myocardial infarction. , 1977, The New England journal of medicine.

[41]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[42]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[43]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[44]  D.,et al.  Regression Models and Life-Tables , 2022 .